BI’s Article search uses Boolean search capabilities. If you are not familiar with these principles, here are some quick tips.

To search specifically for more than one word, put the search term in quotation marks. For example, “workers compensation”. This will limit your search to that combination of words.

To search for a combination of terms, use quotations and the & symbol. For example, “hurricane” & “loss”.

Login Register Subscribe

J&J recalls sunscreens after carcinogen found


(Reuters) — Johnson & Johnson is voluntarily recalling five Neutrogena and Aveeno brand aerosol sunscreen products in the United States after detecting a cancer-causing chemical in some samples.

The New Jersey-based company said on Wednesday that consumers should stop using the products and discard them after internal testing found low levels of benzene in some sprays.

The move comes months after online pharmacy Valisure filed a petition with the U.S. Food and Drug Administration, saying it had found levels of benzene that were higher than recommended in several products that provide protection or relief against sunburns, including sprays and lotions.

CVS Health said on Thursday it had also halted sales of two of its sunburn healing products.

Benzene is classified as a substance that could potentially cause cancer depending on the level and extent of exposure.

J&J, whose shares were down 1%, said benzene is not an ingredient in its sunscreen products and it is investigating the cause of the contamination.

“Daily exposure to benzene in these aerosol sunscreen products at the levels detected in our testing would not be expected to cause adverse health consequences,” the company said.

J&J’s recalled aerosol sunscreens are Neutrogena Beach Defense, Neutrogena Cool Dry Sport, Neutrogena Invisible Daily defense, Neutrogena Ultra Sheer and Aveeno Protect + Refresh.





Read Next

  • High court rejects J&J appeal over Risperdal drug

    (Reuters) — The U.S. Supreme Court rejected a bid by Johnson & Johnson to overturn a $70 million jury verdict against the pharmaceutical company for its failure to warn about risks associated with off-label uses of its antipsychotic drug Risperdal.